Innovative Treatment Offering Mainstay Medical's flagship product, ReActiv8, is the first FDA-approved restorative neuromodulation device for chronic low back pain, highlighting their leadership in minimally invasive pain management solutions and creating opportunities to expand into chronic pain treatment markets.

Recent Clinical Validation The successful enrollment and publication of the five-year follow-up neuromodulation study demonstrates solid clinical evidence supporting ReActiv8, which can be leveraged to engage hospitals, clinics, and insurance payers for increased adoption.

Strategic Expansion Mainstay has expanded its office footprint to Dublin and other European locations, signaling a focus on international growth and collaboration, which opens avenues for partnerships, distribution channels, and regional market penetration.

Significant Investment A recent $125 million equity financing led by Gilde Healthcare signals strong investor confidence and provides resources for scaling commercialization efforts, R&D, and expanded sales outreach in the neuromodulation sector.

Growing Market Presence With a focus on neuromodulation for chronic low back pain and recent clinical trials, Mainstay Medical is positioned to capitalize on increasing demand for alternative pain therapies amid rising healthcare costs and an aging population.